The aim of this study is to examine the impact of haematological cancers on quality of life (QoL). A review of the international literature was conducted from the databases ‘PsycInfo’ and ‘Medline’ using the keywords: ‘haematological cancer’, ‘quality of life’, ‘physical’, ‘psychological’, ‘social’, ‘vocational’, ‘professional’, ‘economic’, ‘cognitive’, and ‘sexual’. Twenty-one reliable studies were analysed. Among these studies, 12 showed that haematological cancer altered overall QoL, 8 papers found a deterioration of physical dimension, 8 papers reported on functional and role dimensions, 11 papers reported on the psychological component and 9 on the social component. Moreover, one study and two manuscripts, respectively, reported deteriorated sexual and cognitive dimensions. Our review demonstrates that the different dimensions of QoL are deteriorated by haematological malignancies and, probably, by the side effects of treatment.

Blood Cancer Journal (2015) 5, e305; doi:10.1038/bcj.2015.29; published online 24 April 2015

INTRODUCTION

Haematological cancers include various diseases (Hodgkin’s lymphoma, non-Hodgkin’s lymphoma, leukaemia and multiple myeloma. The term leukaemia comprises acute myeloid leukaemia, chronic myelogenous leukaemia, acute lymphoblastic leukaemia and chronic lymphoblastic leukaemia); they can affect children, young adults and the elderly, and their incidence increases with age. As liquid tumours moving in the blood or lymph, acute or chronic diseases, with side effects induced by different treatments, are unique. Just as these diseases are distinct entities showing many differences from solid tumours, so too is the manner in which they are managed. In 1999, leukaemias and lymphomas accounted for approximately 8% of all cancers in adults. The 5-year survival rates vary from 47% to 95% depending on the malignancy.

Quality of life (QoL) is usually impaired in the elderly: the biological nature and course of treatment of haematological cancer differ among children and adults, with long-term survival outcomes favouring young people diagnosed and treated as children.

Our paper also focuses on health-related QoL (QoL), a factor reflecting the individual’s assessment of his/her life at any one time relative to his/her previous state and prior experience. Health-related QoL is multidimensional and temporal, relating to a state of functional, physical, psychological and social/family well-being. Compared with the general population, the health-related QoL of cancer patients is worse in most dimensions.

This review describes the QoL and the different problems that patients with haematological malignancies encounter.

MATERIALS AND METHODS

Search strategy

A review was conducted from databases ‘PsycInfo’ and ‘Medline’, searching for studies published between 1990 and 2011 with keywords: ‘haematological cancer’, ‘quality of life’, ‘physical’, ‘psychological’, ‘social’, ‘vocational’, ‘professional’, ‘economic’, ‘cognitive’, and ‘sexual’ appearing in the abstracts.

We used nine combinations for all databases: (1) ‘QoL and haematological cancer’, (2) ‘haematological cancer and physical’, (3) ‘haematological cancer and psychological’, (4) ‘haematological cancer and social’, (5) ‘haematological cancer and cognitive’, (6) ‘haematological cancer and economic’, (7) ‘haematological cancer and professional’, (8) ‘haematological cancer and vocational’, and (9) ‘haematological cancer and sexual’.

Criteria for inclusion/exclusion. Prospective, comparative, exploratory, longitudinal or cross-sectional studies, assessing the QoL or health-related QoL, were analysed. Papers focusing on lymphoma, leukaemia or myeloma patients with chemotherapy, radiotherapy or blood transfusion in periods of remission or relapse were included. However, retrospective studies with other forms of cancer and reviews of the literature were excluded.

Quality assessment and levels of evidence. The studies had to be based on reliable methodological procedure (large population study, standardized tools and relevant statistical methods) and meet the criteria of a table that describes five levels of evidence (Level I: high-quality prospective study (all patients were enrolled at the same point in their disease with 80% follow-up of patients); Level II: retrospective study, untreated controls from a randomized control trial, lesser prospective study (patients enrolled at different
points in their disease or < 80% follow-up): Level III: case control study; Level IV: case series; Level V: expert opinion) in prognostic studies (investigating the effect of a patient’s characteristic on the outcome of the disease). We considered only level I and II studies.

**Data synthesis.** Studies were analyzed by dimensions of QoL and symptoms (description of QoL in Table 1).

**RESULTS**

**Article identification**

In total, 82 studies emerged: 73 studies for ‘Psychnfo’ and 9 studies for ‘Medline’. There were 21 studies for combination 1, 14 for combination 2, 14 for combination 3, 9 for combination 4, 11 for combination 5, 3 for the combination 6, 10 for the combination 7 and 0 for the combinations 8 and 9. By limiting inclusion to studies that provided evidence of the impact of cancer on QoL, we selected 21 studies.

**Methodological characteristics.** One paper presented the level of evidence I and 20 level II. One paper presented the methodological characteristics that provided evidence of the impact of cancer on QoL, we combined 5, 3 for the combination 6, 10 for the combination 7 and 0 for the combinations 8 and 9. By limiting inclusion to studies that provided evidence of the impact of cancer on QoL, we selected 21 studies.

**Patient population.** In total, 7349 patients (3987 patients with lymphoma, 2303 with leukemia, 711 with myeloma, 6 patients with amyloidosis and 1 with myelofibrosis; 341 no specified patients) were included in the studies (average age of 54.8 years).

One study focussed on the cognitive functioning of lymphoma patients by comparing two groups (test group and no-test group (diagnosis unknown)). Another paper examined the QoL, without specifying the number of patients per diagnosis. The health-related QoL was studied in acute lymphoblastic leukemia, myelofibrosis or unclassified leukemia patients, but the authors did not specify the sample size of patients per diagnosis. There were 1171 control groups with haematological patients and healthy subjects in 3 studies.

**QoL and health-related QoL of haematological cancer patients**

**Overall QoL.** Twelve papers showed that haematological cancer negatively affect overall QoL and health-related QoL. We noted a strong association between anaemia and QoL in lymphoma patients before chemotherapy. We found an impairment of QoL in multiple myeloma patients at diagnosis, at the beginning of treatment and during treatment. In chronic lymphoblastic leukemia patients with chemotherapy and in multiple myeloma and acute lymphoblastic leukemia patients at the start of chemotherapy. The latter study found that QoL was more deteriorated in patients with relapses, in comparison to patients who had no relapse, even at the onset of treatment. Moreover, QoL was worse in patients with an advanced stage of disease.

Chronic lymphoblastic leukemia patients had impaired health-related QoL compared with the general population. Compared with healthy controls, chronic lymphoblastic leukemia patients with chemotherapy reported a lower QoL. Non-Hodgkin’s lymphoma survivors with active disease presented a worse QoL compared with short- or long-term survivors. Moreover, one paper found a better QoL in Hodgkin’s lymphoma survivors diagnosed 10–15 years previously than patients diagnosed 5–9 years ago.

QoL improved after aerobic exercise training programme and was better in non-Hodgkin’s lymphoma patients meeting public health exercise guidelines, compared with those who did not. Nevertheless, one study found that QoL of chronic lymphoblastic leukemia patients was similar to or better than published population. However, one study demonstrated that QoL improved during and after chemotherapy in aggressive non-Hodgkin’s lymphoma patients.

**General health.** Five reports investigated the general health in haematological population. For multiple myeloma and non-Hodgkin’s lymphoma patients, their physical health and mobility were the most frequent domains affected by the disease. Two studies noted that non-Hodgkin’s lymphoma patients had a worse general health and that Hodgkin’s lymphoma survivors presented lower general health compared with the population. In another study comparing general health in patients treated with usual care or aerobic exercise training programme, aerobic exercise training patients had better general health than the other patients. However, after chemotherapy, general health improved in non-Hodgkin’s lymphoma patients in one study.

**Physical dimension.** Eight studies showed that haematological cancer deteriorates the physical component of QoL. Some patients negatively perceived their physical well-being after bone marrow transplantation. Four other studies showed that physical function was affected in multiple myeloma patients and that older patients presented more reduced physical functioning than younger patients. Non-Hodgkin’s lymphoma survivors with active disease demonstrated worse physical functioning compared with disease-free survivors and population. Aerobic exercise training programme patients had better cardiovascular fitness than usual care patients. Long-term Hodgkin’s lymphoma survivors diagnosed 10–15 years earlier reported better physical functioning than survivors diagnosed 5–9 years before. For chronic lymphoblastic leukemia patients, physical functioning was significantly deteriorated compared with the healthy controls.

Fatigue, lack of vitality and energy: Ten papers found that fatigue was one of the most prevalent symptoms experienced in haematological patients. Compared with population, chronic lymphoblastic leukemia patients had impaired health-related QoL for fatigue. For 5% of haematological patients, fatigue was the main symptom with insomnia, in particular in acute leukemia and highly malignant lymphoma patients. One paper reported that levels of fatigue in Hodgkin’s lymphoma and chronic lymphoblastic patients were higher than patients in healthy controls, even for years after treatment. Having severe illnesses in Hodgkin’s lymphoma survivors was positively associated with fatigue. Another study showed that lymphoma patients who reported concentration and memory difficulties demonstrated much fatigue; symptom less pronounced in aerobic exercise training programme patients compared with usual care patients. These findings are consistent with the results found in another report.

Three studies noted that patients with bone marrow transplantation and Hodgkin’s lymphoma survivors treated by radiotherapy or chemotherapy presented a lack of energy. For vitality, patients diagnosed 5–9 years before presented a greater lack of vitality than those diagnosed 10–15 years before. Finally, non-Hodgkin’s lymphoma patients reported less vitality compared with population.

Pain: Painful sensations were frequent in haematological patients for five studies. Pain was the most distressing problem for multiple myeloma, monoclonal gammopathy of unknown significance (MGUS) and leukemia and lymphoma patients. In the latter study, older patients had more pain than younger patients. Similar results were found in non-Hodgkin’s lymphoma patients who reported more bodily pain than the general population. However, during chemotherapy, less pain...
| Article        | Design   | Population Details | Disease status/treatment | Procedure | Psychometrics instruments | Results                                                                 |
|---------------|----------|--------------------|---------------------------|-----------|--------------------------|-------------------------------------------------------------------------|
| Cull et al.15  | Comparative | Test group: 91 patients: - 55 HL - 36 NHL No-test group: 109 patients | Disease-free Chemotherapy | Patients completed the instruments and returned them with a form giving preferred times for objective testing | QLQ-C30 HADS MFI BMFQ Memory aids NART PASAT RBMT | Poor QoL in complainers of memory problems No-test group reported better cognitive functioning but more fatigue than the test group (U = 2.0, P = 0.05) Test group: 30% patients reported difficulty in concentrating, 52% in remembering things, 63% memory impairment, 13% possible anxiety and 10% possible depression |
| Zittoun et al.24 | Longitudinal | 179 acute leukaemia patients | Chemotherapy or BMT | T1: 1 day after the end of chemotherapy or BMT T2: 10 days later the end of chemotherapy T3: 21 days after the end of chemotherapy | QLQ-C30 HADS Leukaemia/BMT module | Lack of appetite (T1 = 64%, T2 = 53%, T3 = 49%; P = 0.03), fever (T1 = 24%, T2 = 47%, T3 = 22%; P = 0.001), nausea (T1 = 38%, T2 = 23%, T3 = 16%; P = 0.001), vomiting (T1 = 35%, T2 = 17%, T3 = 16%; P = 0.001), and hair loss (T1 = 19%, T2 = 54%, T3 = 60%; P = 0.001) High frequency of anxiety and depression over time Trend to improvement at the end of treatment |
| Heinonen et al.19 | Longitudinal | 109 patients: - 32 CML - 39 AML - 15 ALL - 13 MDS - 5 MM - 2 NHL - 2 AA - 1 myelofibrosis | Allogeneic BMT | T1: ≤12 months after BMT T2: 12 to ≤36 months after BMT T3: 36 to ≤60 months after BMT T4: >60 months after BMT | FACT-BMT POMS ADL Scale MOS-SS SSQ6 | T1: worse perception of physical well-being (P = 0.000, PV = 20%), anxiety (<12: MS = 9.8; s.d. = 5.0; over 12: MS = 7.6; s.d. = 4.2; F = 4.1), mood disturbance (<12: MS = 49.1; s.d. = 25.0; F = 4.8) Deterioration of availability and satisfaction with social support Most of patients could carry on with their daily activities without any help Functional well-being negatively affected (T1 = 16.8%, T2 = 27.1%, T3 = 21.5%, T4 = 34.6%) because of lack of energy and sleeping disorders |
| Persson et al.25 | Longitudinal | 16 patients: - 7 AL - 9 HML | Chemotherapy | T1: start of treatment T2: 4 months after treatment T3: 8 months T4: 12 months T5: 16 months T6: 20 months T7: 24 months | QLQ-C30 | T1: Deterioration of QoL, role and social functioning (more important in AL than HML patients) with fatigue, dyspnoea and sleep disturbances Deterioration of QoL in patients with relapses than those without relapse T7: Deterioration of role, social, cognitive and emotional functioning and poor QoL, essentially in patients with relapses Deterioration of role and social functioning more important in AL than HML patients |
| Wettergren et al.32 | Comparative | 357 subjects: - 121 HL survivors - 236 CG | Long-term survivors Radiation, chemotherapy or combined modality | Scales sent by postal mail Respondents were promised a movie ticket if they participated in the study | SEIQoL-DW | HL survivors reported leisure and finance less frequently than CG (leisure: HL survivors = 31.4% and CG = 47.9%; df = 1; P = 0.003; finance: HL survivors = 29.8% and CG = 41.5%; df = 1; P = 0.03) Fatigue, loss of energy in HL patients (10.7%; N = 13 on 121; MS = 3.0; s.d. = 1.0) |
| Article | Design | Population | Disease status/treatment | Procedure | Psychometrics instruments | Results |
|---------|--------|------------|--------------------------|-----------|--------------------------|---------|
| Sherman et al. | Pilot | 61 patients: - 52 MM - 5 MGUS - 4 amyloid | Patients newly admitted to the transplant programme | Assessment prior to starting local protocols for conditioning and transplant | SF-12 POMS-F PG-SGA BPI HADS FACIT | Major symptoms: nutritional deficits, deterioration of physical functioning, fatigue and pain, emotional distress, disrupted sexual functioning and difficulties with body image |
| Rüffer et al. | Comparative | 1753 subjects: - 818 HL survivors - 935 CG | Long-term survivors Radiotherapy, chemotherapy Combined modality treatment | In 1995, the authors had contacted 1981 patients, who were enrolled in the German Hodgkin Studies Patients with a current status of complete remission were contacted to participate in this study | QLQ-S QLQ-C30 LQ SQ MFI | All levels of fatigue are high even years after treatment and higher than those of the CG: GF: Patients: MS = 37.6; s.d. = 29.1/CG: MS = 30.9; s.d. = 23.2; P < 0.001 PF: Patients: MS = 32.6; s.d. = 29.2/CG: MS = 25.0; s.d. = 24.2; P < 0.001 RA: Patients: MS = 28.0; s.d. = 26.1/CG: MS = 21.4; s.d. = 21.8; P < 0.001 MF: Patients: MS = 26.6; s.d. = 26.8/CG: MS = 21.8; s.d. = 23.5; P < 0.001 RM: Patients: MS = 19.8; s.d. = 20.1/CG: MS = 16.9; s.d. = 18.1; P < 0.001 Association between severe illnesses with fatigue |
| Gulbrandsen et al. | Comparative | Data from two prospective Nordic Myeloma Study Group Trials: - 221 patients < 60 years treated with high-dose chemotherapy - 203 patients > 60 years treated with MP | Patients newly diagnosed with MM, with addition to low-dose IFN alpha 2b to conventional treatment with MP | Data obtained from prospective trials | QLQ-C30 | At diagnosis, most distressing problems: pain, fatigue, reduced physical functioning, limitations in role functioning and reduced QoL |
| Frick et al. | Comparative | 46 MM 20 NHL 13 other diseases | Complete remission: 6 patients Partial remission: 52 patients No change: 15 patients Progressive disease: 1 patient Not available PBSCT: 5 patients | Randomisation: - individualised Psychotherapy immediately after PBSCT until 6 months after PBSCT - from 6 months after PBSCT until 1 year after - to a CG receiving ‘treatment as usual’ | QLQ-C30 SEIQoL-DW | Most frequent domains nominated by the patients: family (89%), hobbies/pastimes (74%), physical health (mobility) (70%), profession/occupation (51%), social life/friends (47%) and partnership (33%) |
| Article          | Design      | Population  | Disease status/treatment | Procedure                                                                 | Psychometrics instruments | Results                                                                                                                                 |
|------------------|-------------|-------------|--------------------------|---------------------------------------------------------------------------|---------------------------|-----------------------------------------------------------------------------------------------------------------------------------------|
| Merli et al.22   | Longitudinal  | 91 aggressive NHL | Chemotherapy            | T1: diagnosis and before treatment T2: during chemotherapy T3: 1 month after the end of chemotherapy | QLQ-C30                  | T1: association between anaemia and poor QoL T2: improvements of QoL, pain (√0.003), appetite (√0.006), sleep (√0.015) and GH (√0.027), except diarrhoea and social activity T3: improvements of QoL (√0.05), global health (√0.011), appetite (√0.0001), emotional functioning (√0.01) and role (√0.05), reductions of pain (√0.02), sleep disorders (√0.007) and constipation (√0.04) |
| Holzner et al.20 | Longitudinal  | 76 CLL 152 HC | Chemotherapy            | T1: baseline T2: 3 months after baseline T3: 6 months after baseline T4: 12 months after baseline | QLQ-C30                  | Lower QoL in CLL patients compared with HC Physical functioning: effect size medium (√0.56; √0.001) Role and cognitive functioning: effect size small (√0.43, √0.01 and √0.27, √0.1) More symptoms in CLL patients compared with HC: fatigue (√0.81), nausea and vomiting (√0.69), constipation (√0.69), appetite loss (√0.68) and dyspnoea (√0.44) Lower emotional and social QoL in female than in male patients |
| Vallance et al.31 | Retrospective | 438 NHL survivors: - 283 with chemotherapy - 68 with chemotherapy and radiation - 47 with radiation - 16 with surgery - 4 with immunotherapy - 36 with BMT | Questionnaire mailed to patients | FACT-An                                                                 |                           | Better QoL in NHL meeting public health exercise guidelines than NHL not meeting guidelines |
| Santos et al.27  | Cross-sectional | 107 patients: - 54 NHL - 18 AML - 10 ALL - 25 MM | In treatment: - 42 with intravenous chemotherapy - 47 with oral medication - 5 with radiotherapy - 55 with monitoring | Instruments applied during face-to-face interviews QLQ-C30 |                           | Deterioration of QoL essentially in MM patients, contrary to patients with other cancers |
| Mols et al.24    | Comparative  | 116 long-term HL survivors e - 48 patients for the 5–9 year survivors - 68 patients for the 10–15 year survivors | Off-treatment | Survey conducted at the ECR SF 36 QoL-CS |                           | Better QoL in patients diagnosed 10–15 years ago compared with patients 5–9 years ago Lower GH and lack of energy in patients diagnosed 10–15 years ago than patients diagnosed 5–9 years ago Lower general and mental health, social functioning and vitality in patients diagnosed 5–9 years ago, compared with normative sample |
| Mols et al.23    | Comparative  | 221 NHL Sample size for population is not specified | Long-term survivors (5–15 years postdiagnosis) | Recruited from the ECR SF-36 QoL-CS |                           | Patients diagnosed from 10 to 15 years earlier reported better psychological (√0.17*) and social (√0.21**) well-being than patients diagnosed from 5 to 9 years earlier Compared with population, patients reported worse GH (√0.001), less vitality (√0.001), higher scores for pain (√0.001) and problems with work or obtaining health-care insurance and home mortgage |
Table 1. (Continued)

| Article                  | Design  | Population | Disease status/treatment                                                                 | Procedure                                                                 | Psychometrics instruments | Results                                                                 |
|--------------------------|---------|------------|------------------------------------------------------------------------------------------|---------------------------------------------------------------------------|----------------------------|-------------------------------------------------------------------------|
| Shanafelt et al.28       | Comparative | 1482 CLL  | Majority of patients with low-stage disease at diagnosis 40.3% of patients with chemotherapy and/or monoclonal antibody | Between June and October 2006                                              | FACT-G, BFI               | QoL and social and functional dimensions were similar to or better than population norms QoL was worse in patients with advanced stage of disease Lower emotional well-being in CLL patients, compared with population and patients with other types of cancer |
| Else et al.16            | Comparative | 431 CLL   | Chemotherapy                                                                             | Randomisation into the Leukaemia Research Fund CLL4 trial                 | QLQ-C30                   | Impaired HRQoL for the fatigue, sleep disturbance, role functioning and dyspnoea in CLL patients compared with population |
| Strasser-Weippl and Ludwig13 | Randomized clinical trial | 92 MM     | Chemotherapy                                                                             | Questionnaires presented to patients during the first study visit of the clinical trial Conventional treatment | QLQ-C30                   | Impairment of QoL at onset on therapy                                    |
| Courneya et al.14        | Longitudinal | 122 patients: | 62 patients with UC                                                                       | T0: baseline T1: postintervention T2: 6-month follow-up                   | FACT-An, Happiness Scale Depression Short Form Center for Epidemiological Studies Depression Scale STAI SF-12 | T1: better physical functioning (mean group difference, +9.0; CI = 2.0 to 16.0; P = 0.012), cardiovascular fitness (P < 0.001), QoL (P = 0.021), happiness (P = 0.004) and GH (P < 0.001) and attenuation of fatigue (P = 0.013) and depression (P = 0.005) in AET compared with UC patients T2: better happiness (P = 0.034), and attenuation of depression (P = 0.009) in AET, comparatively UC patients |
| Johnsen et al.21         | Cross-sectional | 470 patients: | 269 patients had lymphoma stage 1 or 2                                                   | Scales, information letter and consent form send by mail                  | QLQ-C30                   | Symptoms experienced by patients: fatigue (55%), insomnia (46%) and pain (37%) Impairments: role (49%) and physical functions (34%) More problems (physical, role, social functions, pain and constipation) in MM in comparison to other patients More reduced in physical (OR² = 1.53; 95% CL = 1.36–1.74; P < 0.001) and role functions (OR² = 1.32; 95% CL = 1.16–1.51; P < 0.001), constipation (OR² = 1.47; 95% CL = 1.22–1.78; P < 0.001), appetite loss (OR² = 1.28; 95% CL = 1.08–1.51; P = 0.004) and pain (OR² = 1.28; 95% CL = 1.13–1.45; P < 0.001) in older patients, compared with younger patients, but less financial difficulties (OR² = 0.76; 95% CL = 0.65–0.89; P < 0.001) in older patients More nausea (OR² = 2.98; 95% CL = 1.30–6.83; P = 0.010) and appetite loss (OR² = 3.14; 95% CL = 1.33–7.41; P = 0.009) in recently hospitalised patients than outpatients |
| Article            | Design  | Population                      | Disease status/treatment | Procedure                             | Psychometrics instruments | Results                                      |
|-------------------|---------|---------------------------------|--------------------------|---------------------------------------|---------------------------|----------------------------------------------|
| Smith et al.      | Comparative | 761 NHL survivors: - 109 patients with 'active disease' - 150 'short-term survivors' - 502 'long-term survivors' | STS (2-4 years postdiagnosis) LTS (≥5 years postdiagnosis) | Scales send by mail | SF-36, FACT-G, FACT-LYM, IOC, PTSD Checklist | Lower QoL, physical (mean (s.d.), 41.1 (11.9)) and mental health (mean (s.d.), 45.4 (11.5)) (all P < 0.01) in individuals with active disease, compared with survivors |

**Abbreviations:** AA, acute amyloid; ADL, Activities of Daily Living Scale (Katz et al., 1970); AET, aerobic exercise training; AL, acute leukaemia; ALL, acute lymphoblastic leukaemia; AML, acute myeloid leukaemia; BFI, Brief Fatigue Inventory (Mendoza et al., 1999); BMFQ, Brief Mental Fatigue Questionnaire (Bentall et al., 1993); BMT, bone marrow transplantation; BPI, Brief Pain Inventory (Cleeland, 1989); CG, control group; CML, chronic myelogenous leukaemia; ECR, Eindhoven Cancer Registry; FACT-An, Functional Assessment of Cancer Therapy—Anaemia (Cella, 1997); FACT-BMT, Functional Assessment of Cancer Therapy—Bone Marrow Transplant (McQuellon et al., 1997); FACT-G, Functional Assessment of Cancer Therapy-General (Cella et al., 2003); FACT, Functional Assessment of Chronic Illness Therapy (Cella, 1997); GF, general fatigue; GH, general health; HADS, Hospital Anxiety and Depression Scale (Snith et Zigmund, 1983); HRQoL, health-related quality of life; HL, Hodgkin's lymphoma; HML, highly malignant lymphoma; IFN, interferon; IOC, Impact Of Cancer (Zebrack et al., 2008); LSQ, Life Situation Questionnaire (Joly et al., 1996); LTS, long-term survivors; MA, mean age; MCS, Mental Component Summary; MDS, myelodysplastic syndrome; MF, mental fatigue; MFI-20, Multidimensional Fatigue Inventory (Smet et al., 2000); MM, multiple myeloma; MGUS, monoclonal gammopathy of unknown significance; MIRT, Myeloma Institute for Research and Therapy; MOS SS, Medical Outcome Study Social Support (Sherbourne et Stewart, 1991); MP, Melphalan and Prednisone; NART, National Adult Reading Test (Nelson, 1991); NHL, Non-Hodgkin's Lymphoma; PASAT, Paced Auditory Serial Addition Task (Gronwall & Sampson, 1974); PF, Physical Fatigue; PBSCT, peripheral blood stem cell transplantation; PCS, Physical Component Summary; PG-SGA, Patient-Generated Subjective Global Assessment (Ottery, 1996); POMS, Profile of Mood States-Meaningful; POMS-F, Profile of Mood States—Fatigue Scale (McNair et al., 1992); PTSD Checklist, Posttraumatic Stress Disorder Checklist (Weathers et al., 1993); QLQ-C30, Quality of Life Questionnaire C30 (Aaronson et al., 1983); QLQ-S, Quality of Life Questionnaire—Survivors (Spangers et al., 1993); QoL, quality of life; QoL-CS, quality of life—cancer survivors; RA, reduced activity; RBMT, Rivermead Behavioural Memory Test (Wilson et al., 1991); RM, reduced motivation; SEIQoL-DW, Schedule for the Evaluation of the Individual Quality of Life-Direct Weighting (Browne et al., 1997); SF-12, Short Form 12 items (Ware, 1995); SF-36, Short Form 36 items; SSQ6, Brief Measure of Social Support (Sarason et al., 1987); STAI, Spielberger State Anxiety Inventory (Spielberger, 1993); STS, short-term survivors; UC, usual care. *P < 0.05; **P < 0.01. *Patients who did not present for psychometric testing with respect to age, sex, employment, educational status, diagnosis, therapy received or duration of treatment. MA not specified in the manuscript. Staged using Durie and Salmon classification. MA not specified, most patients are between 30 and 49 years. This register identifies all patients newly diagnosed with cancer in the southern part of the Netherlands.
was experienced by aggressive non-Hodgkin’s lymphoma patients in only one study. 22

Sleep disorders: Four studies found that sleep was affected by haematological cancer. 16,19,22,25 Sleep disorders were prevalent in acute leukaemia and highly malignant lymphoma patients at the start of treatment. 25 Compared with the general population, chronic lymphoblastic leukaemia patients presented more sleep disorders, 16 related to functional well-being. 19 An improvement was found in sleep disturbances during and after chemotherapy in aggressive non-Hodgkin’s lymphoma patients. 22

Digestive symptoms: Digestive symptoms may occur during haematological disease in four studies. 22,24,28 Among the most common problems in acute leukaemia patients, we found lack of appetite, weight loss, nausea and vomiting, 1 day after the end of chemotherapy or bone marrow transplantation. However, these symptoms had improved 10 and 21 days after the end of treatment. 23 Older and recently hospitalised patients had more constipation, nausea and loss of appetite than younger patients and outpatients. 21 Moreover, non-Hodgkin’s lymphoma patients presented diarrhoea during chemotherapy but showed constipation 1 month after the end of treatment. 22 Finally, chronic lymphoblastic leukaemia patients showed more nausea and vomiting, constipation and appetite loss than healthy controls. 20 Dyspnoea: In three studies, dyspnoea, predominant with chemotherapy, was one of the most common symptoms in acute leukaemia and highly malignant lymphoma patients 25 and in chronic lymphoblastic leukaemia patients 16,20 and lymphoma patients. 22

Nutrition: In one study, nutritional deficits predominated in multiple myeloma and MGUS patients, treated with transplant. 29 Fever: Only one study mentioned the problem of fever in acute leukaemia during chemotherapy. 33

Functional and role dimensions. Two studies focussed on the functional dimension. 19,28 Negatively affected after a bone marrow transplantation. However, in one study could most patients carry on with their daily activities without any help 1 year after bone marrow transplantation. 19 Moreover, some authors found that daily functioning was similar or better than the population norms. 28

Concerning role, six studies focussed on this dimension. 16,18,20,22,25 One study analysed the deterioration of role function in leukaemia, multiple myeloma or lymphoma patients. 22 Role was affected in leukaemia and lymphoma 22 and multiple myeloma patients, 18 essentially in older patients. Compared with the general population, chronic lymphoblastic lymphoma patients had impaired role functioning for two studies. 16,20 However, improvement of role was observed 1 month after the end of chemotherapy in non-Hodgkin’s lymphoma patients. 22

Psychological dimension. Eleven studies showed that haematological cancers affect psychological QoL. 14,15,19,20,23,24,28–30,32,33 One paper found that patients diagnosed 10–15 years earlier reported better psychological well-being than patients diagnosed 5–9 years ago. 22 Lymphoma patients with chemotherapy presented possible anxiety and depression 15 and we noted a high frequency of anxiety and depression in acute leukaemia patients, with a trend to improvement at the end of treatment. 33 One study suggested that patients experienced more anxiety and mood disturbance after bone marrow transplantation compared with those with a longer follow-up. 19 Hodgkin’s lymphoma or non-Hodgkin’s lymphoma patients receiving aerobic exercise training programme reported less depression and greater happiness compared with those who did not participate in the programme. 14 Individuals with active disease demonstrated worse mental health functioning compared with population and disease-free survivors. 30 Additional studies reported that emotional distress was present in multiple myeloma, MGUS, amyloid and chronic lymphoblastic leukaemia patients. 20 Finally, chronic lymphoblastic leukaemia patients presented lower emotional well-being compared with the general population. 24,28 Moreover, Hodgkin’s lymphoma survivors presented a different and positive vision of life after disease. 32

Cognitive dimension. Two papers focussed on the cognitive functioning. 15,20 The cognitive area was significantly deteriorated in chronic lymphoblastic leukaemia patients, compared with healthy controls, 20 and lymphoma patients with memory problems had a lower QoL. 15

Social, professional and economic dimensions. Nine papers showed that social, professional and financial QoL were affected by haematological cancer. 17,19–21,23–25,28,32 One report found a deterioration of social functioning in leukaemia and lymphoma patients with chemotherapy. 25 Chronic lymphoblastic leukaemia patients presented a lower social QoL, mainly women. 20 Another study found the same finding in patients diagnosed 5–9 years earlier compared with patients diagnosed 10–15 years before. 24 In one study, the availability of, and satisfaction with, social support declined after bone marrow transplantation. 19 The domain of family was affected in 89% of haematological patients. 17 However, in one paper, the social functioning of chronic lymphoblastic leukaemia patients was similar to or better than that of the general population. 28

Furthermore, one paper showed that Hodgkin’s lymphoma survivors mentioned the topics of leisure and finance less frequently than controls. 32 Older patients had fewer financial difficulties than outpatients, and multiple myeloma patients had a worse social QoL compared with those with other haematological cancers. 21 Finally, most frequent domains mentioned were hobbies/pastimes, partnerships, profession and social life and friends, 17 and difficulties to obtain health-care insurance and life insurance. 23

Sexual dimension. One study focussed on the sexual component 29 and found that multiple myeloma or MGUS patients presented sexual difficulties associated with body image. 28 The problem of body image could be associated with hair loss mentioned in another paper. 33

DISCUSSION

The general findings show that the haematological disease negatively affects overall QoL. 13,14,16,18,20,22,24,25,27,28,30,31 Compared with the general population, fatigue, pain or vitality were the more exposed aspects of QoL, which were specifically deteriorated during an advanced stage of haematological cancer. 26 Compared with the general population, haematological patients had an adverse general health. 23 These results confirm other findings concerning cancer populations. 37

Fatigue was the most prevalent physical symptom. 14,16,18,21,25,26,29,32,33 Most of the samples included elderly patients, and the progressive loss of autonomy in older people is not conducive to maintaining physical QoL. Haematological patients were more susceptible to fatigue than others because of the comorbidity and side effects due to treatment. 38 Moreover, the benefits of physical programme on physical well-being were demonstrated. 25 Similar data were found in Hodgkin’s lymphoma survivors, an improvement in physical functioning and cardiovascular fitness being observed after exercise. 39 The other physical symptoms were common to patients with other forms of cancers 40 as well as breast cancer patients. 41,42

Only one study found that haematological patients can manage acts of daily life without the need for support after bone marrow transplantation. 19 However, older and multiple myeloma patients experienced more reduced role function than younger patients and subjects with other diagnoses. 21 Indeed, the multiple myeloma patients were older than patients with other diagnoses.
and advanced age proved to be a predictor of symptoms. Role was more affected in haematological patients than in the general population. Because of physical disabilities, it is plausible that familial or social missions were disturbed.

Mostly, psychological QoL was found to be worse. One study noted that aerobic exercise training programme helped maintain good mental QoL. This may be due to the involvement of social interaction and a process of being distracted from one’s cancer and treatments, a finding already made in advanced cancer patients. Moreover, emotional benefits occurred after patients with breast cancer followed a sports programme.

Furthermore, haematological cancer damaged social, professional and financial QoL. Having cancer may improve social and familial relations by increasing the intensity of support and the availability of family caregivers. Conversely, emotional distress can affect the family sphere, and interpersonal relationships are likely to move towards the feeling of ambiguity. The deterioration of social well-being could be associated with QoL in gynaecological survivors. Moreover, one finding by establishing that economic stress was negatively associated with QoL in gynaecological survivors. Otherwise, the time since diagnosis may also have an impact on social QoL: in two studies, patients diagnosed 10–15 years earlier presented a better social QoL than those diagnosed 5–9 years before.

These findings were similar among families of patients with a head and neck cancer. Some studies found that professional life was negatively affected in patients. Another study strengthened this finding by establishing that economic stress was negatively associated with QoL in gynaecological survivors. Moreover, one paper showed an increase in disability days in patients with breast, lung and gastrointestinal cancers. These consequences can lead to social isolation and frustration.

Sexual activity, related to body image, was also reduced. Body image could be an important aspect of our criteria, with the fear of loss of masculinity or femininity and self-image. Other forms of cancer such as gynaecological malignancies also affected patients’ sex life.

With regard to cognitive functioning, haematological patients presented several memory and concentration disturbances. Similar results were found in cancer patients, in whom cognitive deficits were observed after chemotherapy. Physical, psychological, social and professional problems may be associated with the effects of treatment modalities. QoL was particularly affected in multiple myeloma and chronic lymphoblastic leukaemia patients, treated by chemotherapy or transplantation, in older patients, and in patients with active disease or an advanced stage of disease. Therefore, it would be interesting to conduct a further review with a synthesis of articles that highlight the impact on QoL of treatments recommended for a haematological malignancy.

The potential limitations of this review concern the literature search. Others involve the complexity in interpreting and measuring QoL, the heterogeneity of samples and the loss of subjects during research due to poor medical conditions, death or refusal.

CONCLUSION
The major strength of our review is the reliability of the selected studies. It shows that haematological cancer patients have a poor QoL or health-related QoL compared with the general population. These findings hold regardless of the type of disease, the treatment modality and the stage of the disease. Generally, we found similar outcomes in other cancers, such as fatigue, which was greater in haematological patients. In theoretical terms, QoL is a complex concept that encompasses various aspects of life and is similar to well-being, so the very meaning of the notion is debatable. Clinically, it is important to analyse QoL early in the course of care. Some types of intervention may prove helpful such as physical programmes, which may be considered as a form of functional care intervention, and other supportive actions, such as psychotherapy which can improve physical and mental functioning.

CONFLICT OF INTEREST
The authors declare no conflict of interest.

REFERENCES
1 Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Gralnick HR et al. Proposals for the Classification of the Acute Leukaemias French-American-British (FAB) Co-operative Group. Brit J Haematol 1976; 33: 451–458.
2 Ireland R. Haematological malignancies: the rationale for integrated haematopathology services, key elements of organization and wider contribution to patient care. Histopathology 2011; 58: 145–154.
3 Zebrack B. Quality of life of long-term survivors of leukemia and lymphoma. J Psychosoc Oncol 2000; 18: 39–59.
4 Pulte D, Gondos A, Brenner H. Trends in survival after diagnosis with hematologic malignancy in adolescence or young adulthood in the United States, 1981-2005. Cancer 2009; 115: 4973–4979.
5 Lesko LM. Hematological malignancies. Handbook of Psychooncology: Psychological Care of the Patient with Cancer. Oxford University Press: New York NY, USA, 1989; pp 218–231.
6 Aaronson NK, Meyrowitz BE, Bard M, Bloom JR, Fawzy I, Feldstein M et al. Quality of life research in oncology. Past achievements and future priorities. Cancer 1991; 67: 839–843.
7 van Den Beek-van Everdingen MHJ, de Rijke JM, Kessels AG, Schouten HC, van Kleef M, Patijn J. Quality of life and non-pain symptoms in patients with cancer. J Pain Symptom Manag 2009; 38: 216–233.
8 Chao NJ, Tierney DK, Bloom JR, Long GD, Barr TA, Stallbaum BA et al. Dynamic assessment of quality of life after autologous bone marrow transplantation. Blood 2009; 120: 825–830.
9 Ferrell BR, Hassey Dow K, Grant M. Measurement of the quality of life in cancer survivors. Qual Life Res 1995; 4: 523–531.
10 Baker F, Denniston BE, Haffer SC, Liberatos P. Change in health-related quality of life of newly diagnosed cancer patients, cancer survivors, and controls. Cancer 2009; 115: 3024–3033.
11 Baumann R, Pütz C, Röhrig B, Höffken K, Wedding U. Health-related quality of life research in oncology. Past achievements and future priorities. Cancer 1991; 17: 1–3.
12 Strasser-Weippl K, Ludwig H. Psychosocial QOL is an independent predictor of overall survival in newly diagnosed patients with multiple myeloma. Eur J Haematol 2008; 81: 374–379.
13 Cosmeiya KS, Sellar CM, Steinwion C, McNeeley ML, Peddle CJ, Friedreich CM et al. Randomized controlled trial of the effects of aerobic exercise on physical functioning and quality of life in lymphoma patients. J Clin Oncol 2009; 27: 4605–4612.
14 Cull A, Hay C, Love SB, Mackie M, Smets E, Stewart M. What do cancer patients mean when they complain of concentration and memory problems? Brit J Cancer 1996; 74: 1674–1679.
15 Else M, Smith AG, Cocks K, Richards SM, Crofts S, Wadie R et al. Patients’ experience of chronic lymphocytic leukaemia: baseline health-related quality of life results from the LRF CLL4 trial. Brit J Haematol 2008; 143: 690–697.
16 Frick E, Borasio GD, Zehentner H, Fischer N, Burned I. Individual quality of life of patients undergoing autologous peripheral blood stem cell transplantation. Psychooncology 2004; 13: 116–124.
17 Holzner B, Kemmler G, Kopp M, Nguyen-Van-Tam D, Sperner-Unterweger B, Greil R. Quality of life of patients with chronic lymphocytic leukemia: results of a longitudinal investigation over 1 yr. Eur J Haematol 2004; 72: 381–389.
18 Gullbrandsen N, Hjemstad MJ, Wolleif F. Interpretation of quality of life scores in multiple myeloma by comparison with a reference population and assessment of the clinical importance of score differences. Eur J Haematol 2004; 72: 172–180.
19 Heinonen H, Volin L, Uutela A, Zevon M, Barrick C, Ruutu T. Quality of life and factors related to perceived satisfaction with quality of life after allogeneic bone marrow transplantation. Ann Hematol 2001; 80: 137–143.
20 Holzer B, Klemmer G, Kopp M, Nguyen-Van-Tam D, Spener-Unterweger B, Greil R. Quality of life of patients with chronic lymphocytic leukemia: results of a longitudinal investigation over 1 yr. Eur J Haematol 2004; 72: 381–389.
21 Johnsen AT, Tholstrup D, Petersen MA, Pedersen L, Groenvold M. Health related quality of life in a nationally representative sample of haematological patients. Eur J Haematol 2009; 83: 139–148.
Merli F, Bertini M, Luminari S, Mozzana R, Berté R, Trottini M et al. Quality of life assessment in elderly patients with aggressive non-Hodgkin's Lymphoma treated with anthracycline-containing regimens. Report of a prospective study by the Intergruppo Italiano Linfomi. Haematologica 2004; 89: 973–978.

Mols F, Aaronson NK, Vingerhoets AJJM, Coebergh JW, Vreugdenhil G, Lybeert MLM et al. Quality of life among long-term non-Hodgkin lymphoma survivors: a population-based study. Cancer 2007; 109: 1659–1667.

Mols F, Vingerhoets AJJM, Coebergh JW, Vreugdenhil G, Aaronson NK, Lybeert MLM et al. Better quality of life among 10-15 year survivors of Hodgkin's lymphoma compared to 5-9 year survivors: a population-based study. Eur J Cancer 2006; 42: 2794–2801.

Persson L, Larsson G, Ohlsson O, Hallberg IR. Acute leukaemia or highly malignant lymphoma patients’ quality of life over two years: a pilot study. Eur J Cancer Care 2001; 10: 36–47.

Rüffer JU, Flechtnner H, Traills P, Josting A, Lathan B et al. German Hodgkin Lymphoma Study Group. Fatigue in long-term survivors of Hodgkin's lymphoma: a report from the German Hodgkin Lymphoma Study Group (GHSG). Eur J Cancer 2003; 39: 2179–2186.

Santos FRM, Kozasa EH, Chauffaille Mde L, Colleoni GW, Leite JR. Psychosocial adaptation and quality of life among Brazilian patients with different haematological malignancies. Psy cosmos Res 2006; 60: 505–511.

Shanafelt TD, Bowen D, Venkat C, Slager SL, Zent CS, Kay NE et al. Quality of life in chronic lymphocytic leukemia: an international survey of 1482 patients. Brit J Haematol 2007; 139: 255–264.

Sherman AC, Coleman EA; Griffith K, Simonton S, Hine RJ, Cromer J et al. Use of a supportive care team for screening and preemptive intervention among multiple myeloma patients receiving stem cell transplantation. Support Care Cancer 2003; 11: 568–574.

Smith SK, Zimmerman S, William CS, Zebrack BJ. Health status and quality of life among non-Hodgkin lymphoma survivors. Cancer 2009; 115: 3312–3323.

Valance JKH, Courneya KS, Jones LW, Reiman T. Differences in quality of life between non-Hodgkin's lymphoma survivors meeting and not meeting public health exercise guidelines. Psychooncol 2005; 14: 979–991.

Wettergren L, Björkholm M, Axdorph H, Coebergh JW, Vreugdenhil G, Lybeert MLM et al. Quality of life among long-term non-Hodgkin lymphoma survivors: a population-based study. Cancer 2007; 109: 1659–1667.

Wettergren L, Björkholm M, Axdorph H, Coebergh JW, Vreugdenhil G, Lybeert MLM et al. Quality of life among long-term non-Hodgkin lymphoma survivors: a population-based study. Cancer 2007; 109: 1659–1667.

Flechtnner H, Rüffer JU, Ferrata S, Ruszniewski M. Assessment of quality of life during intensive chemotherapy or bone marrow transplantation. Psychooncol 1999; 8: 64–73.

Shipp MA, Harrington DP, Anderson JR, Armitage JO, Bonadonna G, Brittinger G et al. A predictive model for aggressive non-Hodgkin's lymphoma. New Engl J Med 1993; 329: 987–994.

Flechtnner H, Rüffer JU, Henry-Amar M, Mellink WA, Sieber M, Ferme C et al. Quality of life assessment in Hodgkin's disease: a new comprehensive approach. First experiences from the EORTC/GELA and GHSG trials. EORTC Lymphoma Coop erative Group. Groupe D'Etude des Lymphomes de L'Adulte and German Hodgkin Study Group. Ann Oncol 1998; 9: 5147–5154.

Jones LW, Eves ND, Peterson BL, Garst J, Crawford J, West MJ et al. Safety and feasibility of aerobic training on cardiopulmonary function and quality of life in postsurgical nonsmall cell lung cancer patients: a pilot study. Cancer 2008; 113: 3430–3439.